Please try another search
For the three months ended 31 March 2022, KOREA UNITED PHARM INC revenues increased 27% to W63.59B. Net income increased 25% to W11.47B. Revenues reflect Othe Proucts segment increase of 25% to W25.36B, Clanza segment increase from W1.62B to W4.34B, South Korea segment increase of 28% to W57.43B, Other Foreign segment increase of 32% to W3.96B.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 63591.66 | 56613.13 | 57131.47 | 57182.47 |
Gross Profit | 35098.4 | 31576.79 | 31564.18 | 31512.36 |
Operating Income | 11110.33 | 7767.2 | 8600.74 | 9204.43 |
Net Income | 11466.39 | 2083.55 | 10803.48 | 6592.79 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 397481.8 | 380032.75 | 374362.77 | 365730.3 |
Total Liabilities | 90207.17 | 79323.82 | 75827.35 | 78110.3 |
Total Equity | 307274.63 | 300708.93 | 298535.43 | 287620 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | 7849.68 | 44085.21 | 26795.48 | 16493.82 |
Cash From Investing Activities | -21532.22 | -17697.94 | -10806.75 | -8826.71 |
Cash From Financing Activities | 142.47 | -8197.45 | -7994.56 | -5349.41 |
Net Change in Cash | -13197.76 | 20348.21 | 10140.22 | 3096.9 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review